Track IBRX stock price swings, biotech earnings, technical analysis, and forecast. Is IBRX stock a buy on cancer vaccine hopes? Analyst targets and trial risks ahead.
Introduction
ImmunityBio develops cancer immunotherapies and vaccines. Its lead drug Anktiva treats bladder cancer using natural killer cells. Investors watch IBRX stock now after volatile March 2026 trading and FDA approvals. Biotech swings with trial data and funding cycles amid tight capital markets.
Sector rotates between hope and cash burn fears. IBRX stock price jumped from $3 to $10+ recently then pulled back to $8.45 intraday March 13. Everyday investors weigh breakthrough odds against dilution.
Latest stock Price & Trend
IBRX stock traded at $8.45 midday March 13, 2026, up 8.06% from prior close per real-time Nasdaq data. Prior day March 12 closed $7.82 after 5.44% drop on 14.5 million shares. Five-day trend volatile up 3% net from March 6 $8.67 peak.
One-month rocket from $6.33 Feb 3 to $10.44 March 2 then retraced 19%. Three-month surge 120%+ from January lows near $3. Year-to-date gains exceed 150% demolishing indexes.
52-week extremes hit $12.45 high, $2.51 low. Bullish momentum persists despite profit-taking, signaling conviction in clinical pipeline for investors.
Technical Analysis
Support firms at $7.80 matching March 12 lows. Resistance $9.60 tests from March 4 highs. RSI likely overbought 70+ after rally—RSI measures buying exhaustion above 70 signaling pullback risk.
MACD bullish but momentum fading post-crossover. 50-day average surged above 200-day forming golden cross March confirming uptrend—this pattern predicts rallies when short-term beats long-term trend.
Volume exploded 33 million March 4, 41 million March 2 versus 20 million average. IBRX technical analysis warns beginners of volatility near resistance.
Analyst Ratings & Price Targets
5 analysts rate Strong Buy consensus. Average target $14.40 for 2026, high $24, low $5 representing 335% upside from recent lows. Wall Street Zen, Public.com bullish on Anktiva.
Firms highlight FDA breakthrough designation. Strong Buy sentiment implies massive rerating potential—critical for IBRX forecast evaluation.
Insider Activity
CEO Patrick Soon-Shiong holds 10%+ stake post-SPAC. No recent selling reported in March filings amid rally. Management aligned with clinical success.
Trends show founder confidence through volatility. IBRX insider activity supports long-term conviction play.
Valuation Analysis
Trailing P/E negative on R&D losses, forward estimates speculative. Price-to-sales N/A pre-commercial. Revenue growth awaits Anktiva launch post-approval.
Cash burn $100 million+ quarterly, $400 million runway. $2 billion market cap undervalued versus $10 billion+ peak if approved. Vs. biotech peers, IBRX stock fairly valued on pipeline but binary risk.
Recent Earnings & Catalysts
Q4 showed trial progress, cash preservation. Anktiva FDA Priority Review accepted with PDUFA June 2026. Phase 3 NMIBC data exceeded endpoints.
Catalysts dominate: BLA filing complete, potential 2026 launch. News drove March volatility lifting IBRX stock price 200%+ from January.
Bullish Case
Anktiva addresses 80k bladder cancer cases yearly. NK cell platform expands to solid tumors. $20 billion TAM across indications.
Priority Review accelerates revenue. IBRX revenue growth explodes post-approval realistically.
Bearish Case
FDA rejection delays commercialization. Dilution funds burn rate. Competition from checkpoint inhibitors.
Binary trial risk crushes valuation. Biotech funding winter persists.
Market Sentiment & Investor Psychology
Short interest spikes 20%+ during pullbacks. March 2026 puts active $10.50, $14.50 strikes traded. Institutions accumulate steadily.
Retail momentum chasers dominate volume. Sentiment optimistic on approval odds, momentum bias strong.
Short-Term Outlook
Overbought RSI caps $9.60 test. Profit-taking likely retests $7.80 support. News-driven swings expected next weeks pre-PDUFA.
Medium to Long-Term Outlook
Immunotherapy market grows 15% yearly to $150 billion. NK cell differentiation vs. CAR-T. Cash funds key trials through 2027.
Approval de-risks valuation. IBRX forecast favors accumulate sub-$7 for biotech believers.
FAQ
Is IBRX stock a buy right now?
Speculative buy post-pullback, $14.40 target justifies risk.
What is the IBRX stock price target?
Strong Buy consensus $14.40 2026 average.
What are major risks for IBRX stock?
FDA rejection, dilution, trial failures.
Next IBRX earnings date?
Late May 2026 Q1 expected.
IBRX RSI analysis current?
Overbought 70+, pullback risk elevated.
Suggestion
- Compare with Opendoor stock analysis
- See immunotherapy sector outlook
- Read NK cell therapy forecast
Conclusion
Watchlist IBRX stock ahead PDUFA. Anktiva approval transforms valuation but binary risks dominate—small positions only.
Disclaimer: This article is for informational purposes only and not financial advice.